InsidersTradesSigma
Follow the EXAGEN INC. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, EXAGEN INC. has recorded 45 reports. Market capitalisation: €107.5m. The latest transaction was reported on 16 March 2026 (Attribution). Among the most active insiders: ABALLI JOHN. The full history is openly available.
45
Insider Decl.
n/a
Thresholds
€440,833
6 ops.
Buy Volume
€3m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate EXAGEN INC. Strong Buy (bullish), based on 7 analysts. Average price target: US$8.57.
49Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,622 of 29,062 companies
20.1
score / 100
Value13
Quality28
FCF yld-13%
Earn yld-18%
EV/EBITDA·
ROE-194%
Gross mgn58%
Net mgn-30%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 March 2026
Declarations45 total
75,000 shares@ US$3.1646.1% of flowCommon StockSEC:0001449439-26-000005:0
150,000 shares0Common StockSEC:0001843113-26-000006:0
15,698 shares@ US$3.625.5% of flowCommon StockSEC:0001843113-26-000004:0
11,430 shares@ US$3.610.040% mcap4.9% of flowCommon StockSEC:0001843113-26-000002:0
1,584 shares@ US$3.610.0055% mcap1.4% of flowCommon StockSEC:0001449439-26-000003:0
31,787 shares@ US$11.81610.37% mcap45.1% of flowCommon StockSEC:0001843113-25-000003:0
20,466 shares@ US$9.790.20% mcap48.6% of flowCommon StockSEC:0001628280-25-041688:0
350,000 shares@ US$3.3063.2% of flowCommon StockSEC:0001140361-25-010700:0
8,621 shares@ US$2.4651.7% of flowCommon StockSEC:0001274737-25-000013:0
112,500 shares0Common StockSEC:0001274737-25-000010:0
15,000 shares0Common StockSEC:0001274737-25-000011:0
200,000 shares@ US$3.300236.8% of flowCommon StockSEC:0001140361-24-047978:0
22,298 shares@ US$2.9815.1% of flowCommon StockSEC:0001274737-24-000096:0
Canonical exit: 13 Feb 2025 (T+90)
24,305 shares@ US$2.815.4% of flowCommon StockSEC:0001274737-24-000094:0
Canonical exit: 12 Feb 2025 (T+90)
225,000 shares0Common StockSEC:0001274737-24-000084:0
40,401 shares@ US$1.926.0% of flowCommon StockSEC:0001274737-24-000052:0
Canonical exit: 14 Aug 2024 (T+90)
9,297 shares@ US$1.908922.8% of flowCommon StockSEC:0001274737-24-000017:0
9,804 shares@ US$1.911.5% of flowCommon StockSEC:0001274737-24-000015:0
175,000 shares0Common StockSEC:0001274737-24-000012:0
75,000 shares0Common StockSEC:0001274737-24-000013:0
6,738 shares@ US$1.949117.1% of flowCommon StockSEC:0001274737-24-000009:0
33,819 shares@ US$1.74514.7% of flowCommon StockSEC:0001274737-23-000094:0
9,803 shares@ US$2.1421.6% of flowCommon StockSEC:0001274737-23-000091:0
167 shares@ US$3.11050.1% of flowCommon StockSEC:0000899243-23-015986:0
Canonical exit: 13 Sept 2023 (T+90)
3,667 shares@ US$2.299311.0% of flowCommon StockSEC:0001274737-23-000014:0
25 of 45 declarations
关于 EXAGEN INC.
Exagen Inc. 是一家美国医疗技术公司，专注于自身免疫和风湿病诊断。该公司在美国纳斯达克市场上市，股票代码为 XGN。其业务核心是开发和商业化 AVISE® 实验室检测产品组合，旨在支持复杂风湿病、自身免疫疾病和自身免疫相关疾病（包括系统性红斑狼疮和类风湿关节炎）的鉴别诊断、预后和监测。旗舰产品 AVISE® CTD 检测于 2012 年商业推出，至今仍是核心收入驱动力。([sec.gov](https://www.sec.gov/Archives/edgar/data/1274737/000127473725000019/exdx-20241231.htm)) Exagen 成立于 2002 年，最初在新墨西哥州注册成立，后于 2003 年迁至特拉华州。公司于 2019 年 1 月更名为 Exagen Inc.。其主要行政办公室位于加利福尼亚州维斯塔，在美国一个活跃的生命科学区域设有总部。([sec.gov](https://www.sec.gov/Archives/edgar/data/1274737/000127473726000009/exdx-20251231.htm)) 从商业模式的角度来看，Exagen 是一家专注的专业公司，而非广泛的诊断综合企业。其竞争定位基于专有生物标志物、经过同行评审的临床证据以及旨在解决自身免疫护理中主要痛点（即可能延迟诊断并导致重复检测的重叠症状）的诊断工作流程。管理层将公司描述为服务于风湿病专家、初级保健医生、其他专科医生、患者、医院、医疗保健系统和支付方，其运营报告为一个单一部门。([sec.gov](https://www.sec.gov/Archives/edgar/data/1274737/000127473725000019/exdx-20241231.htm)) 主要产品线仍是 AVISE® 平台，其中 AVISE® CTD 居于核心地位。近期，Exagen 通过新的生物标志物扩展了该平台，包括针对血清阴性类风湿关节炎和 T 细胞相关生物学的标志物，旨在改善临床鉴别并扩大公司的可寻址用例。公司还强调了更高的平均销售价格，这表明产品组合的改善和商业吸引力的增强。([investors.exagen.com](https://investors.exagen.com/node/9596/pdf)) 最近的运营更新表明业务好转。2025 财年，Exagen 报告收入达到创纪录的 66.6 million 美元，同比增长 20%，同时 AVISE CTD 检测量增加，毛利率提高。2026 年第一季度，公司再次报告季度收入创纪录，达到 17.3 million 美元，期末现金及现金等价物约为 22 million 美元。管理层还预计 2026 年收入为 70 million 至 73 million 美元，并强调 AVISE 平台的持续商业扩张。([investors.exagen.com](https://investors.exagen.com/node/9596/pdf)) 对于法语市场的投资者而言，Exagen 最好被视为一家在纳斯达克上市的美国医疗保健诊断公司，在自身免疫疾病检测领域拥有独特的利基市场。其投资案例结合了专业的临床护城河和不断改善的收入势头，但仍面临报销风险、监管审查以及维持商业执行和资金纪律的需求。([sec.gov](https://www.sec.gov/Archives/edgar/data/1274737/000127473726000009/exdx-20251231.htm))
